EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting acetyl-CoA carboxylases for the treatment of MASLD

María Antonia Mateo-Marín, Michele Alves-Bezerra

Journal of Lipid Research · 2024-12 · 65 (12) · 100676

DOI: 10.1016/j.jlr.2024.100676 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Lipid Research, 2024-12. Verfasst von María Antonia Mateo-Marín und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Biotechnology and Public Health, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Faculty of Medicine, Uni…. Hauptthemen laut MEDLINE: Acetyl-CoA Carboxylase, Fatty Liver. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Universidad de Cádiz, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatic accumulation of triglycerides is a hallmark feature of metabolic dysfunction-associated steatotic liver disease (MASLD). Growing evidence indicates that increased rates of de novo lipogenesis (DNL) are one of the earliest metabolic changes promoting hepatic steatosis in the onset of MASLD. The first step in DNL is catalyzed by acetyl-CoA carboxylases (ACC), which mediate the conversion of acetyl-CoA into malonyl-CoA. Given the critical role of ACC enzymes on DNL, ACC-based therapies have emerged as an attractive approach to address MASLD, leading to the development of pharmacologic inhibitors of ACC. In clinical trials, several of those compounds led to decreased DNL rates and improved hepatic steatosis in patients with MASLD. In this review, we describe the development of ACC dual inhibitors and isoform-specific inhibitors along with their clinical testing using monotherapy and combination therapy approaches. We also discuss their efficacy and safety profiles, identifying potential directions for future research. It is anticipated that advances in ACC-based therapies will be critical to the management of MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acetyl-CoA CarboxylaseFatty LiverHumansAnimalsEnzyme InhibitorsLipogenesis

Stichwörter der Autor:innen

ACC inhibitorsDNLDNL inhibitorsMASLDde novo lipogenesishepatic steatosislipid metabolism

Substanzen

Acetyl-CoA CarboxylaseEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Biomedicine, Biotechnology and Public Health, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Faculty of Medicine, University of Cadiz, Cadiz, Spain.
  • Department of Biomedicine, Biotechnology and Public Health, Biomedical Research and Innovation Institute of Cadiz (INiBICA), Faculty of Medicine, University of Cadiz, Cadiz, Spain. Electronic address: michele.alves@uca.…

Förderung

  • Agencia Estatal de Investigación
  • Universidad de Cádiz
  • Junta de Andalucía

Zitieren

APA

Mateo-Marín, M. A., & Alves-Bezerra, M. (2024). Targeting acetyl-CoA carboxylases for the treatment of MASLD. Journal of Lipid Research, 65(12), 100676. https://doi.org/10.1016/j.jlr.2024.100676

Vancouver

Mateo-Marín MA, Alves-Bezerra M. Targeting acetyl-CoA carboxylases for the treatment of MASLD. Journal of Lipid Research. 2024;65(12):100676. doi:10.1016/j.jlr.2024.100676

BibTeX
@article{MateoMarn2024,
  author = {Mateo-Marín, María Antonia and Alves-Bezerra, Michele},
  title = {Targeting acetyl-CoA carboxylases for the treatment of MASLD},
  journal = {Journal of Lipid Research},
  year = {2024},
  volume = {65},
  number = {12},
  pages = {100676},
  doi = {10.1016/j.jlr.2024.100676}
}
Kostenlos starten →